Institution profile

医療法人 慶昌会 クロエ クリニック 青山

Explore the institution's name, address and registered technologies as published, along with plan classifications, score components and sources.

The ranking reflects only the registration data published by Japan's Ministry of Health, Labour and Welfare; it does not represent treatment outcomes or quality of care. Scoring method →

Source: Ministry of Health, Labour and Welfare public directory of regenerative medicine providers MHLW e-Regenerative Medicine public register · Directory archive date I: 2026-07-19 / II: 2026-09-26 / III: 2026-05-18 · Internet Archive

MHLW e-Regenerative Medicine public registerPublic document number 01C2306006 +4

Location

Prefecture
Tokyo
Address
港区赤坂7−1−15 アトム青山タワー2F

Plan classification

  • Class INot registered
  • Class IIThe medium-risk category under the law.
  • Class IIIThe low-risk category under the law.

Certified committee for regenerative medicine

  • 安全未来特定認定再生医療等委員会
  • JSCSF再生医療等委員会
  • 健康長寿再生医療委員会
  • +1

Public score

66.6/ 100

A · Review level
25.0 / 30
B · Technologies
20.6 / 35
C · Coverage
14.3 / 25
D · Class I / II technologies
6.7 / 10

The public score is calculated from public registration information and does not reflect quality of care. Scoring method →

Position in the overall score distribution

0–100 · Public score
000–9.9 · 0 institutions
01010–19.9 · 0 institutions
2172020–29.9 · 217 institutions
3163030–39.9 · 316 institutions
7564040–49.9 · 756 institutions
2465050–59.9 · 246 institutions
1326060–69.9 · 132 institutions
417070–79.9 · 41 institutions
248080–89.9 · 24 institutions
49090–100 · 4 institutions
This institution 66.6
Public score →100

Registered technologies (5)

Stem cells (all sources) 4
Registered technologies · Japanese originalTechnology areasPlan classification
自己歯髄幹細胞による根管治療後の歯髄再生治療Stem cells (all sources)DentalClass II
アトピー性皮膚炎患者の主症状に対する自己脂肪由来幹細胞による治療Stem cells (all sources)Adipose-derived stem cellsSkinClass II
自己脂肪組織由来幹細胞を用いた三叉神経痛及び顔面神経麻痺の治療Stem cells (all sources)Adipose-derived stem cellsClass II
脂肪由来幹細胞を用いた慢性疼痛に対する治療Stem cells (all sources)Adipose-derived stem cellsClass II
Adipose-derived stem cells 3
Registered technologies · Japanese originalTechnology areasPlan classification
アトピー性皮膚炎患者の主症状に対する自己脂肪由来幹細胞による治療Stem cells (all sources)Adipose-derived stem cellsSkinClass II
自己脂肪組織由来幹細胞を用いた三叉神経痛及び顔面神経麻痺の治療Stem cells (all sources)Adipose-derived stem cellsClass II
脂肪由来幹細胞を用いた慢性疼痛に対する治療Stem cells (all sources)Adipose-derived stem cellsClass II
NK and immune cells 1
Registered technologies · Japanese originalTechnology areasPlan classification
がんの治療と予防を目的とした樹状細胞ペプチドワクチン療法NK and immune cellsClass III
Dental 1
Registered technologies · Japanese originalTechnology areasPlan classification
自己歯髄幹細胞による根管治療後の歯髄再生治療Stem cells (all sources)DentalClass II
Skin 1
Registered technologies · Japanese originalTechnology areasPlan classification
アトピー性皮膚炎患者の主症状に対する自己脂肪由来幹細胞による治療Stem cells (all sources)Adipose-derived stem cellsSkinClass II

Certified committee for regenerative medicine

  • 安全未来特定認定再生医療等委員会
  • JSCSF再生医療等委員会
  • 健康長寿再生医療委員会
  • 一般社団法人 細胞免疫学研究会認定再生医療等委員会

Public document number

  • 01C2306006
  • 01C2604036
  • 01C2509057
  • 03C2505007
  • 02C2505035
Plan classification · Certified committee for regenerative medicine · Public document number
Registered technologiesPlan classificationCertified committee for regenerative medicinePublic document number
アトピー性皮膚炎患者の主症状に対する自己脂肪由来幹細胞による治療Class II安全未来特定認定再生医療等委員会01C2306006
自己脂肪組織由来幹細胞を用いた三叉神経痛及び顔面神経麻痺の治療Class IIJSCSF再生医療等委員会01C2604036
脂肪由来幹細胞を用いた慢性疼痛に対する治療Class IIJSCSF再生医療等委員会01C2509057
自己歯髄幹細胞による根管治療後の歯髄再生治療Class II健康長寿再生医療委員会03C2505007
がんの治療と予防を目的とした樹状細胞ペプチドワクチン療法Class III一般社団法人 細胞免疫学研究会認定再生医療等委員会02C2505035

Other institutions in the same prefecture

← Institution directory
One-to-one advice

Still unsure? Ask an advisor

Use the “Chat with an advisor” button on this page (at the bottom of the screen on mobile, bottom right on desktop) to open a chat with the Stem Cell Japan advice desk. Consultation and coordination are free, and an advisor replies within one working day.

Chat with an advisor